|
IMMUNODEFICIENCY 20
|
0.600 |
GermlineCausalMutation
|
disease |
ORPHANET |
Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity.
|
23006327 |
2012 |
|
IMMUNODEFICIENCY 20
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity.
|
23006327 |
2012 |
|
IMMUNODEFICIENCY 20
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II).
|
8608639 |
1996 |
|
IMMUNODEFICIENCY 20
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa.
|
8609432 |
1996 |
|
IMMUNODEFICIENCY 20
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections.
|
8874200 |
1996 |
|
IMMUNODEFICIENCY 20
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa.
|
8609432 |
1996 |
|
IMMUNODEFICIENCY 20
|
0.600 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Celiac Disease
|
0.320 |
Biomarker
|
disease |
CTD_human |
Celiac disease biomarkers identified by transcriptome analysis of small intestinal biopsies.
|
30097691 |
2018 |
|
Celiac Disease
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
The FcgR2a*519GG and FcgR3a*559CC genotypes have been associated with several autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, nephritis, and possibly to type I diabetes, and celiac disease.
|
20848524 |
2010 |
|
Celiac Disease
|
0.320 |
Biomarker
|
disease |
LHGDN |
We studied the FcgammaRIIa*A519G (rs1801274) and FcgammaRIIIa*A559C (rs396991) single nucleotide polymorphisms in celiac disease families from Hungary and Finland and in celiac disease case-control materials from Hungary and Italy.
|
19140833 |
2009 |
|
Lupus Vasculitis, Central Nervous System
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genetic Variants That Are Associated with Neuropsychiatric Systemic Lupus Erythematosus.
|
26773105 |
2016 |
|
Lupus Meningoencephalitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genetic Variants That Are Associated with Neuropsychiatric Systemic Lupus Erythematosus.
|
26773105 |
2016 |
|
Neuropsychiatric Systemic Lupus Erythematosus
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genetic Variants That Are Associated with Neuropsychiatric Systemic Lupus Erythematosus.
|
26773105 |
2016 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Temporomandibular Joint Dysfunction Syndrome
|
0.200 |
Biomarker
|
disease |
RGD |
Knockdown of Fcγ receptor III in an arthritic temporomandibular joint reduces the nociceptive response in rats.
|
20589683 |
2010 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These bispecific antibodies can recruite NK cells to kill CEA-positive tumor cells, and inhibit tumor growth in vivo, suggesting that these anti-CD16a single domain antibodies are powerful tools to engaging NK cells for cancer therapy.
|
31564196 |
2020 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
|
31396956 |
2020 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD32A<sup>131R</sup> -CR T cells combined with the mAb 8.26 (anti-CD32) and CD16<sup>158F</sup> -CR T cells combined with the mAb 3g8 (anti-CD16) eliminated colorectal carcinoma (CRC), HCT116<sup>FcγR+</sup> cells, in a reverse ADCC assay in vitro.
|
31479522 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
These bispecific antibodies can recruite NK cells to kill CEA-positive tumor cells, and inhibit tumor growth in vivo, suggesting that these anti-CD16a single domain antibodies are powerful tools to engaging NK cells for cancer therapy.
|
31564196 |
2020 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis.
|
30457672 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The shift towards nonclassical CD14<sup>dim</sup>CD16+ monocytes in peripheral blood due to TNFi treatment was seen in both AS and RA.
|
30642076 |
2019 |
|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A significant correlation was observed between the reactivity of FcγRIIIA-expressing cells to IgGH complexed with a specific HLA-DR allele and the odds ratio for HLA-DR allele's association with RA.
|
30721990 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
|
30429531 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The percentages of both pre-chemotherapy and post-chemotherapy circulating CD16+CD56+NK cells were negatively correlated with the prognosis of CRC.
|
31493232 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Circulating CD16+CD56+ NK cells can be used as a screening and diagnostic/staging tool for CRC.
|
31636738 |
2019 |